Novartis

Novartis

Web: Novartis external link
Lieu: Bâle
Domaine: Médecine/Pharmacologie
Lié à:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
#display_name

Médecine 24.2
If approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation CHMP opinion based on positive data from pivotal study of patients with BRAF V600-positive NSCLC With new targeted therapy, BRAF becomes fourth actionable oncogenic driver of lung cancer, similar to EGFR, ALK and ROS1 Bas
Médecine 23.2

Priority Review based on Phase III study results showing 16.6 month median progression-free survival in previously untreated ALK+ metastatic NSCLC patients on Zykadia vs.

Médecine 26.1

Innovative AcrySof IQ PanOptix Toric i ntraocular lens (IOL) extends Alcon's trifocal PanOptix IOL portfolio to a wider range of patients -   CE-marked in November 2016, this IOL offers excellent n

Économie 25.1

Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback FY net sales (0% cc ) in line with prior year due to st

Médecine 31.1

Votubia is the first adjunctive treatment approved in the EU specifically for partial-onset seizures in children and adults with tuberous sclerosis complex (TSC) -   Approval addresses unmet need a

Médecine 26.1

Novartis Access-to-medicine programs reached approximately 52 million patients, including first-year deliveries through the innovative Novartis Access program -   Novartis improved position in key

Médecine 6.1

Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevat



Link

Medicine and Life Sciences